Cardiff Oncology, Inc. Common Stock

CRDFNASDAQ • USD
0.82 USD
↘ 0.03 (3.62%)🟢LIVE (AS OF 11:08 AM EST)
🟢Market: OPEN

Shares of Cardiff Oncology, Inc. Common Stock (CRDF) are trading at $0.82. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place CRDF at a fair price relative to peers.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.87
High?$0.91
Low?$0.80
Prev. Close?$0.85
Volume?1.1M
Avg. Volume?1.2M
VWAP?$0.86
Rel. Volume?0.88x
Bid / Ask
Bid?$0.69 × 100
Ask?$0.92 × 100
Spread?$0.23
Midpoint?$0.80
Valuation & Ratios
Market Cap?66.1M
Shares Out?77.8M
Float?68.5M
Float %?88.1%
P/E Ratio?N/A
P/B Ratio?2.35
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Employees
31
Market Cap
56.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
1997-05-22
Address
11055 FLINTKOTE AVENUE
SAN DIEGO, CA 92121
Phone: 858-952-7570
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
85
Short Sent.?
39
Piotroski F-Score?3/9Weak
Altman Z-Score?-15.62Distress
Confidence?46%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?17.89%High
Short Interest?12.3M
Days to Cover?30.8
Free Float68.5M
Avg Daily Volume397.9K
Settlement Date2026-10-30
Financial Health
Current Ratio?4.21Strong
Quick Ratio?4.21Strong
Cash Ratio?1.45Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
67
2.35CHEAP▾
P/S?
Peers
100
S&P
3
118.29HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
96.72HIGH▾
Returns & Efficiency
ROE?
S&P
3
-134.1%WEAK▾
ROA?
S&P
3
-103.5%WEAK▾
Cash Flow & Enterprise
FCF?$-39942000
Enterprise Value?$54.1M
Fundamentals ratios updated end of day